NEPHROPLUS - Nephrocare Health Services

📊 NSE: NEPHROPLUS 🏢 Healthcare Service Provider 📅 Last Updated: 11/13/2025 15:25

💰 Financial Performance

Geographic Revenue Split

Not disclosed in available documents. The company maintains its Global Corporate Headquarters in Madhapur, Hyderabad, Telangana.

⚙️ Operational Drivers

📈 Strategic Growth

Growth Strategy

The company is transitioning from a private to a public limited entity (formerly Nephrocare Health Services Private Limited), as evidenced by its listing on BSE (Scrip Code: 544647) and NSE (Symbol: NEPHROPLUS). This transition typically facilitates growth through access to public capital markets for expansion and increased brand visibility.

Products & Services

Dialysis treatments and comprehensive renal care services.

Brand Portfolio

Nephroplus

🌍 External Factors

Industry Trends

The company is operating in the healthcare sector with a focus on nephrology. The industry is evolving towards standardized dialysis care and public-private partnerships, positioning Nephroplus as a specialized service provider in the kidney care segment.

Competitive Moat

The company's moat is built on its specialized focus on nephrology and its established network of dialysis centers. Its transition to a public listed entity (BSE: 544647) provides a competitive advantage in terms of capital access and regulatory transparency.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act, 2013 and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company is currently conducting a Postal Ballot (Notice dated January 05, 2026) to seek member approval for special/ordinary resolutions, ensuring compliance with Section 110 of the Act.

Legal Contingencies

Not disclosed in available documents. While the provided documents contain numerous SARFAESI Act notices (e.g., against Shiva Sal Jayalakshmi Tyres and various individuals), these pertain to third-party borrowers and not Nephrocare Health Services Limited.